Journals / Eurasian Journal of Medicine and Oncology / 2019 / Cilt: 3 - Sayı: 1

Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly

Pages
14–21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Acromegaly patients have lower levels of Klotho and FGF-23 and CFR.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Acromegaly is a chronic endocrine disorder that is characterized by hypersecretion of growth hormone.
📊
Key Findings & Data:The purpose of this study was to evaluate coronary flow reserve (CFR) in patients with acromegaly and investigate whether there is an association between fibroblast growth factor-23 (FGF-23) and Klotho levels with coronary microcirculation or not.
💡
Conclusion & Impact:Conclusion: Acromegaly patients have lower levels of Klotho and FGF-23 and CFR.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: Acromegaly is a chronic endocrine disorder that is characterized by hypersecretion of growth hormone. The purpose of this study was to evaluate coronary flow reserve (CFR) in patients with acromegaly and investigate whether there is an association between fibroblast growth factor-23 (FGF-23) and Klotho levels with coronary microcirculation or not. Methods: A total of 54 patients with acromegaly were divided into subgroups: Those with active disease and those who are in biochemical remission (serum insulin-like growth factor-1 level was within the normal range). Along with 31 healthy volunteers, the patients underwent dipyridamole-stress transthoracic Doppler echocardiography. CFR was calculated with the ratio of hyperemic to baseline diastolic peak velocities. Klotho and FGF-23 were measured using an enzyme-linked immunosorbent assay. Results: A total of 42 (%77.8) of acromegaly patients had active disease. Acromegaly patients had lower Klotho and FGF-23 levels compared to in controls. Patients with active disease had higher FGF-23 levels and lower Klotho levels when compared to patients in remission. CFR levels of active group were lower than remission and controls (p=0.001; p=0.043, respectively). Klotho was strongly associated with CFR levels in patients with active disease (r=0.8, p=0.001). Conclusion: Acromegaly patients have lower levels of Klotho and FGF-23 and CFR.

🔖

Cite This Article

TAKIR, M., AKSU, F. (2019). Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 1, 14–21. https://ajindex.com/articles/126025

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395–402
  2. Bengtsson BA, Edén S, Ernest I, Odén A, Sjögren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327–35
  3. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95–102
  4. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 2004;25:102–52
  5. Minniti G, Jaffrain-Rea ML, Moroni C, Baldelli R, Ferretti E, Cassone R, et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol (Oxf) 1998;49:101–6
  6. Fazio S, Cittadini A, Sabatini D, Merola B, Colao AM, Biondi B, et al. Evidence for biventricular involvement in acromegaly: A doppler echocardiographic study. Eur Heart J 1993;14:26–33
  7. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004;89:71–5. 8. van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 2006;16:101–7
  8. Warszawski L, Kasuki L, Sá R, Dos Santos Silva CM, Volschan I, Gottlieb I, et al. Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: A prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 2016;19:582–9
  9. Kırış A, Erem C, Turan OE, Civan N, Kırış G, Nuhoğlu I, et al. Left ventricular synchronicity is impaired in patients with active acromegaly. Endocrine 2013;44:200–6
  10. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, et al. Hypertension in acromegaly and in the normal population: Prevalence and determinants. Clin Endocrinol (Oxf) 2005;63:470–6
  11. Biering H, Knappe G, Gerl H, Lochs H. Prevalence of diabetes in acromegaly and cushing syndrome. Acta Med Austriaca 2000;27:27–31
  12. Maldonado Castro GF, Escobar-Morreale HF, Ortega H, Gómez-Coronado D, Balsa Barro JA, Varela C, et al. Effects of normalization of